Pluribus Labs’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Pluribus Labs's REGN Position: Q2 2022 in Review
Pluribus Labs increased its Regeneron Pharmaceuticals (REGN) stake by 103% in Q2 2022, buying an estimated $314K and bringing the position to 953 shares worth $563K. The position accounts for 1.03% of the portfolio, ranked #25.
Pluribus Labs first reported a position in REGN in Q1 2022 and has held it in 2 quarters since. 1,063 funds tracked by Wall St. Rank hold REGN as of Q2 2022.
- Pluribus Labs held 953 shares of Regeneron Pharmaceuticals worth $563K as of Q2 2022.
- Pluribus Labs bought 483 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $314K.
- Regeneron Pharmaceuticals made up 1.03% of Pluribus Labs's portfolio in Q2 2022, its #25 holding.
- Pluribus Labs first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 2 quarters since.
- 1,063 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.
Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.